Pharmacotherapy of BPD: Current status & future perspectives

Rita M Ryan; Devashis Mukherjee; Stephanie Ford; Krithika Lingappan

doi:10.1016/j.semperi.2023.151819

Pharmacotherapy of BPD: Current status & future perspectives

Semin Perinatol. 2023 Oct;47(6):151819. doi: 10.1016/j.semperi.2023.151819. Epub 2023 Sep 9.

Authors

Rita M Ryan¹, Devashis Mukherjee², Stephanie Ford¹, Krithika Lingappan³

Affiliations

¹ UH Rainbow Babies & Children's Hospital and Case Western Reserve University, Cleveland, OH.
² UH Rainbow Babies & Children's Hospital and Case Western Reserve University, Cleveland, OH. Electronic address: Devashis.Mukherjee@UHhospitals.org.
³ University of Pennsylvania, Philadelphia, PA.

PMID: 37783580
DOI: 10.1016/j.semperi.2023.151819

Abstract

Bronchopulmonary dysplasia (BPD) is a disease exclusive to prematurity and has changed in its definition since Northway first described it in 1967. There have been countless clinical trials evaluating the efficacy of drugs in the treatment and prevention of BPD in human subjects, and an even larger number of animal studies. Despite these, only a handful of drugs are used at the bedside today, primarily due to the lack of consistent efficacy seen in clinical trials or due to reports of adverse effects. This review summarizes the list of the most commonly used drugs and emerging new therapies which target BPD and BPD-related pulmonary hypertension (BPD-PH), including those which have shown promise in human trials but are not yet used routinely.

Keywords: Caffeine; Mesenchymal stem cells; Sildenafil; Steroids; Vitamin A.

Publication types

Review

MeSH terms

Bronchopulmonary Dysplasia* / drug therapy
Bronchopulmonary Dysplasia* / prevention & control
Humans
Hypertension, Pulmonary* / drug therapy
Infant, Newborn
Infant, Premature